Endra Life Sciences INC S-1 registration statements

ENDRA Life Sciences Inc. is launching a public offering of common stock and warrants to raise approximately $95.6 million, primarily to fund a new, untested cryptocurrency treasury strategy while continuing development of its core ultrasound technology.

ENDRA Life Sciences Inc. is launching a public offering of common stock and warrants to raise approximately $118 million, primarily to fund a new treasury strategy focused on holding bitcoin and other cryptocurrencies, while continuing to develop its TAEUS medical technology.

ENDRA Life Sciences Inc. announces a significant strategic shift to allocate the majority of its capital raise proceeds to a cryptocurrency treasury strategy, alongside a renewed focus on its TAEUS technology for metabolic disease management, while addressing ongoing Nasdaq listing compliance issues.

ENDRA Life Sciences is seeking to raise capital through a public offering of common stock, pre-funded warrants, and common stock purchase warrants.

ENDRA Life Sciences launches an offering of common stock and warrants, aiming to raise approximately $4.3 million for working capital and general corporate purposes.

ENDRA Life Sciences is launching a firm commitment public offering of common stock, pre-funded warrants, and accompanying Series A and Series B warrants to raise capital for working capital and general corporate purposes.